EMvision Medical Devices (ASX:EMV) 3-Year EBITDA Growth Rate: -5.70% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EMV EMvision Medical Devices Ltd ASX:EMV
23 GF Score
Price A$1.77
! 3 Warning Signs
View Full Analysis

What is EMvision Medical Devices 3-Year EBITDA Growth Rate?

EMvision Medical Devices ASX:EMV +3.22% 23 3-Year EBITDA Growth Rate is -5.70% as of Dec. 2025. GuruFocus rates ASX:EMV with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, EMvision Medical Devices ranks worse than 72.83% on this metric.

EMvision Medical Devices's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.04.

During the past 3 years, the average EBITDA Per Share Growth Rate was -5.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of EMvision Medical Devices was 45.60% per year. The lowest was -7.40% per year. And the median was 0.95% per year.


EMvision Medical Devices  (ASX:EMV) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


EMvision Medical Devices 3-Year EBITDA Growth Rate Related Terms


ASX:EMV vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, EMvision Medical Devices's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EMvision Medical Devices 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, EMvision Medical Devices's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where EMvision Medical Devices's 3-Year EBITDA Growth Rate falls into.


ASX:EMV
23GF Score
EMvision Medical Devices Ltd ASX:EMV
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EMvision Medical Devices 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -5.70% mean?
EMvision Medical Devices (ASX:EMV) has a 3-Year EBITDA Growth Rate of -5.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for EMvision Medical Devices and its competitors. According to the industry distribution chart, EMvision Medical Devices ranks #504 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 72.8%.
Is EMvision Medical Devices' 3-Year EBITDA Growth Rate too high?
EMvision Medical Devices' current 3-Year EBITDA Growth Rate is -5.70%. Based on the distribution chart, EMvision Medical Devices ranks #504 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, EMvision Medical Devices has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does EMvision Medical Devices' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EMvision Medical Devices ranks #504 out of 692 companies for 3-Year EBITDA Growth Rate. This places EMvision Medical Devices in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for EMvision Medical Devices and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EMvision Medical Devices's current 3-Year EBITDA Growth Rate is -5.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EMvision Medical Devices stock overvalued right now?
EMvision Medical Devices (ASX:EMV) has a current 3-Year EBITDA Growth Rate of -5.70%. The current 3-Year EBITDA Growth Rate is -5.70%. EMvision Medical Devices' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For EMvision Medical Devices (ASX:EMV), the current 3-Year EBITDA Growth Rate is -5.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EMvision Medical Devices Business Description

Address 65 Epping Road, Suite 4.01, Macquarie Park, Sydney, NSW, AUS, 2113
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
23GF Score

Get the complete analysis for ASX:EMV

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.77
Price